MedTrace Logo

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA

NCT00637663 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-03-05

No results posted yet for this study

Summary

This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients currently receiving lamivudine monotherapy.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Entecavir

entecavir 0.5 mg QD

DRUG

Lamivudine

lamivudine 100 mg QD

Sponsors & Collaborators

  • Yonsei University

    collaborator OTHER

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Heo, M.D. Ph.D · Pusan National University

  • Sang Hoon Ahn, M.D.Ph.D · Yonsei Univsersity College of Medicine

  • Jun Yong Park, M.D · Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00637663 on ClinicalTrials.gov